GLTO
Damora Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$21.58
−3.36%Latest reported
- Last report date
- May 12, 2026
- EPS actual
- -$0.62
- EPS estimate
- -$0.39
- Revenue actual
- —
- Revenue estimate
- —
Track record
Trailing twelve quarters
- EPS beats (12Q)
- 6
- EPS misses (12Q)
- 4
- EPS in line (12Q)
- 0
- Avg surprise (4Q)
- -3537.8%
- Revenue beats (12Q)
- —
No earnings call summaries available
Reported history
| Report date | EPS estimate | EPS actual | Surprise | Revenue actual |
|---|---|---|---|---|
| May 12, 2026 | -$0.39 | -$0.62 | Miss -59.89% | — |
| Mar 18, 2026 | $0.90 | -$126 | Miss -14032.42% | — |
| Nov 6, 2025 | — | -$2.36 | — | — |
| May 8, 2025 | — | -$1.92 | — | — |
| Mar 19, 2025 | -$3.12 | -$5.22 | Miss -67.31% | — |
| Nov 1, 2024 | -$3.70 | -$3.39 | Beat 8.38% | — |
| Mar 8, 2024 | -$7.75 | -$5.75 | Beat 25.81% | $1.2M |
| Apr 28, 2023 | -$14 | -$13 | Beat 8.93% | — |
| Mar 9, 2023 | -$14 | -$14 | Beat 3.51% | — |
| Jul 29, 2022 | -$17 | -$17 | Beat 2.90% | — |
| Apr 29, 2022 | -$0.61 | -$17 | Miss -2645.90% | — |
| Feb 17, 2022 | -$14 | -$13 | Beat 5.36% | — |
Reported results against consensus at the time of each report · Surprise is computed from the estimate on record · Data as of May 12, 2026